bone mets: FDA approves Xgeva

For those of us with bone metastases Zometa® is a drug many of us receive to help maintain bone being ravaged by both cancer and treatment. The Federal Drug Administration (FDA) this week approved Xvega®, a new drug developed to delay the onset of skeletal related events (SRE), such as fracture or vertebral compression, that cause pain and require treatment either by radiation or surgery. In studies comparing Xgeva to Zometa, Xgeva showed that SRE were delayed a number of months longer than Zometa.

FDA approves Xgeva to help prevent cancer-related bone injury

F.D.A. Approves a Bone Drug for Cancer Patients, by Andrew Pollock, The New York Times 11-18-10

5 6 7 8
© 2004-2010 Donna Peach. All rights reserved.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s